Cabotegravir/ Rilpivirine

ON DEMAND

The ABCs of CAB: Incorporating Long-acting CABENUVA into Clinical Practice

Learn More

  • Congress Data

    Cabenuva Post CROI 2022 Discussion

    Andrew Zolopa, MD—Head North American Medical Affairs, ViiV Healthcare
    Paula Teichner, PharmD—Regional Medical Lead, Cabotegravir, ViiV Healthcare
    Mark Lewandowski, PharmD —Medical Director, ViiV Healthcare

    ATLAS 2M Week 152 Data - Discussion and Application to Clinical Practice

    Paula Teichner, PharmD—Regional Medical Lead, Cabotegravir
    Jean Van Wyk, MBChB; MFPM—VP and Global Medical Lead, Cabotegravir

    Post-CROI 2021 Webinar

    Andrew Zolopa, MD, VP, Head, North America Medical Affairs

  • Clinical Trials Data

    Cabenuva Post CROI 2022 Discussion

    Andrew Zolopa, MD—Head North American Medical Affairs, ViiV Healthcare
    Paula Teichner, PharmD—Regional Medical Lead, Cabotegravir, ViiV Healthcare
    Mark Lewandowski, PharmD —Medical Director, ViiV Healthcare

    ATLAS 2M Week 152 Data - Discussion and Application to Clinical Practice

    Paula Teichner, PharmD—Regional Medical Lead, Cabotegravir
    Jean Van Wyk, MBChB; MFPM—VP and Global Medical Lead, Cabotegravir

    The ABCs of CAB: Incorporating Long-Acting Cabenuva into Clinical Practice

    Paula Teichner, PharmD, AAHIVP, Regional Medical Lead

    Post-CROI 2021 Webinar

    Andrew Zolopa, MD, VP, Head, North America Medical Affairs